Stuart A. Arbuckle

2019

In 2019, Stuart A. Arbuckle earned a total compensation of $6.9M as EVP & Chief Commercial Officer at Vertex Pharmaceuticals, a 28% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$1,260,000
Option Awards$1,575,011
Salary$770,962
Stock Awards$3,215,952
Other$37,608
Total$6,859,533

Arbuckle received $3.2M in stock awards, accounting for 47% of the total pay in 2019.

Arbuckle also received $1.3M in non-equity incentive plan, $1.6M in option awards, $771K in salary and $37.6K in other compensation.

Rankings

In 2019, Stuart A. Arbuckle's compensation ranked 1,410th out of 13,971 executives tracked by ExecPay. In other words, Arbuckle earned more than 89.9% of executives.

ClassificationRankingPercentile
All
1,410
out of 13,971
90th
Division
Manufacturing
495
out of 5,692
91st
Major group
Chemicals And Allied Products
149
out of 2,189
93rd
Industry group
Drugs
119
out of 1,875
94th
Industry
Pharmaceutical Preparations
90
out of 1,387
94th
Source: SEC filing on April 28, 2020.

Arbuckle's colleagues

We found six more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2019.

2019

Jeffrey Leiden

Vertex Pharmaceuticals

Chairman

2019

Reshma Kewalramani

Vertex Pharmaceuticals

Chief Executive Officer

2019

Amit Sachdev

Vertex Pharmaceuticals

EVP & Chief Patient Officer

2019

Charles Wagner

Vertex Pharmaceuticals

Chief Financial Officer

2019

Paul Silva

Vertex Pharmaceuticals

SVP & Corporate Controller

2019

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

News

You may also like